Reviewed clinical summary · Source-linked · Educational use only

Does Ischemic Preconditioning Help Parathyroid Recovery After Thyroid Surgery?

Hormone Insight visual abstract summarising parathyroid ischaemic preconditioning during thyroid surgery.
Visual abstract for parathyroid ischaemic preconditioning during thyroid surgery.

Clinical Bottom Line

A randomised trial finds parathyroid ischaemic preconditioning does not reduce hypoparathyroidism after thyroidectomy, with only an exploratory recovery signal. PICO summary and commentary.

Summary: In a single-centre trial during total thyroidectomy with central neck dissection, ischaemic preconditioning of the parathyroid glands did not reduce postoperative hypoparathyroidism, though an exploratory analysis suggested faster early parathyroid function recovery.

PICO Summary

ElementDetail
Population135 patients undergoing total thyroidectomy with central neck dissection for differentiated thyroid carcinoma (single centre).
InterventionIntraoperative ischaemic preconditioning: three cycles of 60-second arterial occlusion then 60-second reperfusion (n=67).
ComparisonStandard surgery without preconditioning (n=68).
OutcomeNo significant reduction in postoperative hypoparathyroidism (50.8% vs 41.2%; p=0.265) or protracted hypoparathyroidism (6.0% vs 14.7%; p=0.096). Exploratory: higher early parathyroid function recovery (88.2% vs 64.3%; p=0.025). Hypocalcaemia and surgical complications comparable.
RCT J Invest Surg · 2026

Ischaemic preconditioning of parathyroid glands

RCT · total thyroidectomy + CND · DTC

Trial design
135 thyroidectomy patients Enrolled & assessed RANDOMISED 1:1 Preconditioning 3 cycles 60s occlusion n = 67 Standard surgery No preconditioning n = 68 Postoperative hypoparathyroidism
Proportion reaching endpoint
p=0.265 % with postoperative hypoparathyroidism 50.8% Preconditioning 41.2% Standard surgery ARR+9.6 pp (NS)
Postop hypoPT
50.8% vs 41.2%
p=0.265 (NS)
Protracted hypoPT
6.0% vs 14.7%
p=0.096
Early PT recovery
88.2% vs 64.3%
p=0.025 (exploratory)
Primary endpoint
Negative
No reduction
⬡ Bottom Line

Ischaemic preconditioning did not lower postoperative or protracted hypoparathyroidism. A faster early recovery signal was exploratory only and needs a properly powered confirmatory trial.

Expert Commentary

Postoperative hypoparathyroidism is the bane of thyroid surgery, so a cheap intraoperative manoeuvre that might protect the glands is an appealing idea, and ischaemic preconditioning has a respectable physiological pedigree elsewhere in surgery. The discipline this trial demands, though, is to read the primary endpoint first, and it was negative: the rates of both postoperative and protracted hypoparathyroidism did not differ significantly. The interesting part, faster early parathyroid function recovery, is explicitly exploratory, a secondary signal in a 135-patient single-centre study, and the authors themselves flag it as hypothesis-generating rather than practice-changing. I take that honesty at face value. A single positive exploratory analysis against a negative primary is exactly the pattern that fails to replicate when tested head-on. Can I use this with my patients? Not as an endocrinologist performing surgery, but more to the point, I would not yet advise surgical colleagues to adopt it on the strength of an exploratory finding. It is a promising signal worth a properly powered confirmatory trial with parathyroid recovery as the prespecified primary endpoint. Until then, meticulous gland identification and preservation remain the proven approach.

References

Sheng Q, Zhang P, Zhang T, et al. A randomized trial evaluating intraoperative ischemic preconditioning of parathyroid glands during total thyroidectomy: a signal for earlier parathyroid function recovery. J Invest Surg. 2026;39(1):2613617. doi:10.1080/08941939.2026.2613617

Educational use: Hormone Insight is intended for healthcare professionals and learners. Interpret each summary alongside the primary source, local guidance, and patient-specific clinical judgement.

Subscribe now

Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.

© 2024-2026 Hormone Insight. All rights reserved.